Last reviewed · How we verify
NCT02671890
Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or Metastatic Pancreatic Cancer
Phase 1 trial testing Chemotherapy in Metastatic Pancreatic Adenocarcinoma in 16 participants. Terminated before completion.
8 May 2024
Quick facts
| Lead sponsor | Mayo Clinic |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 16 |
| Start date | 25 February 2016 |
| Primary completion | 8 May 2024 |
| Estimated completion | 11 November 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- Chemotherapy (chemotherapy) — full drug profile →
- Disulfiram (DISULFIRAM) — full drug profile →
- Gemcitabine Hydrochloride — full drug profile →
- Laboratory Biomarker Analysis — full drug profile →
Conditions studied
- Metastatic Pancreatic Adenocarcinoma — all drugs for Metastatic Pancreatic Adenocarcinoma →
- Refractory Malignant Solid Neoplasm — all drugs for Refractory Malignant Solid Neoplasm →
- Stage IV Pancreatic Cancer AJCC v8 — all drugs for Stage IV Pancreatic Cancer AJCC v8 →
Sponsor
Mayo Clinic
Who can join
18 and older, any sex, with Metastatic Pancreatic Adenocarcinoma or Refractory Malignant Solid Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This partially randomized phase I trial studies the side effects and best dose of disulfiram when given together with chemotherapy in treating patients with a solid tumor that does not respond to treatment (refractory) or pancreatic cancer that has spread to other places in the body (metastatic) and to compare whether disulfiram and chemotherapy may reduce tumor induced muscle loss. Weight loss occurs in pancreatic cancer patients and is common in a multitude of other cancers. Patients with metastatic cancer and weight loss sometimes are not able to receive treatment due to physical weakness or debility. Disulfiram is a potential inhibitor of muscle degradation and may reduce tumor induced muscle wasting. Disulfiram may also help chemotherapy work better by making tumor cells more sensitive to the drug. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving chemotherapy with or without disulfiram is a better treatment for refractory solid tumors or metastatic pancreatic cancer.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Copper metabolism in cell death and autophagy.
Xue Q, Kang R, Klionsky DJ, Tang D, et al · · 2023 · cited 504× · PMID 37055935 · DOI 10.1080/15548627.2023.2200554 -
Small Molecule NF-κB Pathway Inhibitors in Clinic.
Ramadass V, Vaiyapuri T, Tergaonkar V. · · 2020 · cited 154× · PMID 32708302 · DOI 10.3390/ijms21145164 -
Drug-induced oxidative stress in cancer treatments: Angel or devil?
Jiang H, Zuo J, Li B, Chen R, et al · · 2023 · cited 130× · PMID 37224697 · DOI 10.1016/j.redox.2023.102754 -
Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance.
Babak MV, Ahn D. · · 2021 · cited 125× · PMID 34440056 · DOI 10.3390/biomedicines9080852 -
The role of ALDH2 in tumorigenesis and tumor progression: Targeting ALDH2 as a potential cancer treatment.
Zhang H, Fu L. · · 2021 · cited 116× · PMID 34221859 · DOI 10.1016/j.apsb.2021.02.008 -
Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells.
Sunami Y, Rebelo A, Kleeff J. · · 2017 · cited 111× · PMID 29295482 · DOI 10.3390/cancers10010003 -
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications.
Tošić I, Frank DA. · · 2021 · cited 100× · PMID 34731785 · DOI 10.1016/j.neo.2021.10.003 -
Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V, Ali M, Small B, Rajendran G, et al · · 2021 · cited 94× · PMID 34604310 · DOI 10.3389/fmolb.2021.741316
Verify or expand the search:
- PubMed search for NCT02671890
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Chemotherapy
Trials testing the same drug.
- NCT07391774 — Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribocic · Phase 3 · not yet recruiting
- NCT07476287 — Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult · Phase 2 · recruiting
- NCT07392892 — A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer · Phase 2, PHASE3 · recruiting
- NCT07288034 — Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatmen · Phase 2 · recruiting
- NCT07078604 — A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati · Phase 2 · recruiting
Other recruiting trials for Metastatic Pancreatic Adenocarcinoma
Currently open trials in the same condition.
- NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
- NCT07226856 — BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent P · Phase 2 · recruiting
- NCT07189195 — TR-002 for the Treatment of Advanced, Unresectable or Metastatic Solid Tumors and Unresectable or Metastatic, Refractory · Phase 1 · recruiting
- NCT06396091 — A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer · Phase 1 · active not recruiting
- NCT06381154 — Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or · Phase 2 · recruiting
Other Mayo Clinic trials
Trials by the same sponsor.
- NCT07126548 — A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men · NA · not yet recruiting
- NCT07221656 — Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration · not yet recruiting
- NCT06891001 — The Utilization of a Shoe Insert on Individuals With Unilateral Greater Trochanteric Pain Syndrome on Single Leg Stance, · NA · not yet recruiting
- NCT07169799 — Impact of Cryotherapy Spray (Tru-Freeze) for the Eradication of Gastric Antral Vascular Ectasia (ICE-GAVE) · NA · recruiting
- NCT07086183 — Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02671890 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mayo Clinic
- Last refreshed: 7 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02671890.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing